[{"id":"94c408ac-7175-4009-9855-94101a5bc215","acronym":"M23-385","url":"https://clinicaltrials.gov/study/NCT05599984","created_at":"2022-10-31T13:56:57.345Z","updated_at":"2025-02-25T14:03:07.565Z","phase":"Phase 1","brief_title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05599984 - M23-385","lead_sponsor":"AbbVie","biomarkers":" EGFR • SEZ6","pipe":" | ","alterations":" EGFR mutation • IDH wild-type","tags":["EGFR • SEZ6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 12/05/2022","start_date":" 12/05/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-19"},{"id":"7d668ceb-425e-4625-a077-dffc5f34f447","acronym":"","url":"https://clinicaltrials.gov/study/NCT05005403","created_at":"2021-08-13T12:53:39.013Z","updated_at":"2024-07-02T16:34:36.863Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab","source_id_and_acronym":"NCT05005403","lead_sponsor":"AbbVie","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • budigalimab (ABBV-181) • ABBV-514"],"overall_status":"Recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 05/04/2026","primary_completion_date":" 05/04/2026","study_txt":" Completion: 05/04/2026","study_completion_date":" 05/04/2026","last_update_posted":"2024-06-10"},{"id":"555f4a0d-f843-45d3-937e-da35717f6f0f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03893955","created_at":"2021-01-18T19:10:50.774Z","updated_at":"2024-07-02T16:34:37.718Z","phase":"Phase 1","brief_title":"A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03893955","lead_sponsor":"AbbVie","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PD-L1 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/21/2019","start_date":" 05/21/2019","primary_txt":" Primary completion: 09/29/2024","primary_completion_date":" 09/29/2024","study_txt":" Completion: 09/29/2024","study_completion_date":" 09/29/2024","last_update_posted":"2024-06-06"},{"id":"514f0a6c-a2ea-4456-9b4e-604c0c92dc8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03639194","created_at":"2023-08-12T16:10:08.643Z","updated_at":"2024-07-02T16:35:19.981Z","phase":"Phase 1","brief_title":"A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer","source_id_and_acronym":"NCT03639194","lead_sponsor":"AbbVie","biomarkers":" SEZ6","pipe":"","alterations":" ","tags":["SEZ6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e budigalimab (ABBV-181) • ABBV-011"],"overall_status":"Completed","enrollment":" Enrollment 132","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 01/25/2024","primary_completion_date":" 01/25/2024","study_txt":" Completion: 01/25/2024","study_completion_date":" 01/25/2024","last_update_posted":"2024-02-09"},{"id":"dad65528-e8ce-42f1-a557-69b26a4858c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03071757","created_at":"2021-01-18T15:07:57.819Z","updated_at":"2024-07-02T16:36:11.278Z","phase":"Phase 1","brief_title":"A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03071757","lead_sponsor":"AbbVie","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e budigalimab (ABBV-181) • revdofilimab (ABBV-368)"],"overall_status":"Completed","enrollment":" Enrollment 139","initiation":"Initiation: 03/21/2017","start_date":" 03/21/2017","primary_txt":" Primary completion: 04/13/2022","primary_completion_date":" 04/13/2022","study_txt":" Completion: 04/13/2022","study_completion_date":" 04/13/2022","last_update_posted":"2022-04-28"},{"id":"5e25c190-7b84-4684-81a8-f9c1a3e15bde","acronym":"","url":"https://clinicaltrials.gov/study/NCT03000257","created_at":"2021-01-17T17:43:13.957Z","updated_at":"2024-07-02T16:36:12.444Z","phase":"Phase 1","brief_title":"A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT03000257","lead_sponsor":"AbbVie","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • budigalimab (ABBV-181) • Rova-T (rovalpituzumab tesirine)"],"overall_status":"Completed","enrollment":" Enrollment 182","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 03/29/2022","primary_completion_date":" 03/29/2022","study_txt":" Completion: 03/29/2022","study_completion_date":" 03/29/2022","last_update_posted":"2022-04-14"}]